Shanghai Huayu Biotechnology

Shanghai Huayu Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the research and development of novel small molecule therapeutics for oncology and metabolic diseases. The company's lead candidate is XCCS605B, a checkpoint kinase 1 inhibitor originally developed by Zhejiang Medicine Co., Ltd. XCCS605B is currently being evaluated in Phase 1 clinical trials as a monotherapy and in combination with other agents, such as gemcitabine and toripalimab, for the treatment of advanced malignant solid tumors. Shanghai Huayu Biotechnology aims to address unmet medical needs in cancer therapy by targeting key cell cycle and DNA damage response pathways.